Llewelyn, Martin, Budgell, Eric, Laskawiec-Szkonter, Magda, Cross, Elizabeth, Alexander, Rebecca, Bond, Stuart, Coles, Phil, Conlon-Bingham, Geraldine, Dymond, Samantha, Evans, Morgan, Fok, Rosemary, Frost, Kevin, Garcia-Arias, Veronica, Glass, Stephen, Gormley, Carine, Grey, Katherine, Hamson, Clare, Harvey, David, Hills, Tim, Iyer, Shabnam, Johnson, Alison, Jones, Nicola, Kang, Parmjit, Kiapi, Gloria, Mack, Damien, Makanga, Charlotte, Mawer, Damian, McCullagh, Bernie, Mirfenderesky, Mariyam, McEwan, Ruth, Nag, Sath, Nagar, Aaron, Northfield, John, O'Driscoll, Jean, Pegden, Amanda, Sivyer, Katy, Santillo, Marta, Krusche, Adele S, Mowbray, Fiona M, Yardley, Lucy, Peto, Tim and Walker, Ann Sarah (2022) Antibiotic Review Kit for Hospitals (ARK-Hospital): a stepped wedge cluster randomised controlled trial. The Lancet Infectious Diseases, 23 (2), P207-221. (doi:10.1016/S1473-3099(22)00508-4).
Abstract
Background: Strategies to reduce antibiotic overuse in hospitals depend on prescribers taking decisions to stop unnecessary antibiotics. There is limited evidence on how to support this. We evaluated a multifaceted behaviour change intervention (ARK) designed to reduce antibiotic use among adult acute/medical inpatients by increasing appropriate decisions to stop antibiotics at clinical review. Methods: We performed a stepped-wedge, cluster (hospital)-randomised controlled trial using computer-generated sequence randomisation of 39 hospitals in 7 calendar-time blocks in the United Kingdom (25/September/2017-01/July/2019). Randomised implementation date was concealed until 12 weeks before implementation, when local preparations were designed to start. Co-primary outcomes were monthly antibiotic defined-daily-doses (DDD) per adult acute/medical admission (hospital-level, superiority) and all-cause 30-day mortality (patient level, non-inferiority, margin 5%). Sites were eligible if they admitted non-elective medical patients, could identify an intervention “champion”, and provide study data. Sites werefollowed for at least 14 months. Intervention effects were assessed using interrupted timeseries analyses within each site, estimating overall effects through random-effects meta analysis, with heterogeneity across prespecified potential modifiers assessed using meta regression.Trial registration: ISRCTN12674243.Findings: Adjusted estimates showed reductions in total antibiotic DDDs per acute/medicaladmission (-4.8% per year, 95% CI: -9.1%,-0.2%) following the intervention. Among7,160,421 acute/medical admissions, there were trends towards -2.7% (95% CI: -5.7%,+0.3%) immediate and +3.0% (95% CI: -0.1%,+6.2%) sustained changes in adjusted30-day mortality. Site-specific mortality trends were unrelated to the site-specific magnitudeof antibiotic reduction (Spearman’s ρ=0.011, p=0.949). Whilst 90-day mortality oddsappeared to increase (+3.9%, 95% CI: +0.5%,+7.4%), this was attenuated excludingadmissions after COVID-19 onset (+3.2%, 95% CI:-1.5%,+8.2%). There was no evidence ofintervention effects on length-of-stay (p>0.4).Interpretation: The weak, inconsistent intervention effects on mortality are likely explained by the post-implementation onset of the COVID-19 pandemic. The ARK intervention resulted in sustained, safe reductions in antibiotic use among adult acute/medical inpatients. Funding: NIHR Programme Grants for Applied Research, RP-PG-0514-20015.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.